Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 1, 2012, Pages 9-18

  Zuberbier, T ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTIHISTAMINIC AGENT; BROMPHENIRAMINE; CETIRIZINE; CHLORPHENIRAMINE; CIMETIDINE; CORTICOSTEROID; CYCLOSPORIN A; DAPSONE; DESLORATADINE; DIPHENHYDRAMINE; FEXOFENADINE; HEPARIN; HYDROXYZINE; IMMUNOSUPPRESSIVE AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; LORATADINE; METHOTREXATE; MIZOLASTINE; MYCOPHENOLIC ACID; OMALIZUMAB; PLACEBO; PROMETHAZINE; RUPATADINE; STEROID; TRIPROLIDINE;

ALERTNESS; ALLERGIC ASTHMA; ALOPECIA; ANEMIA; ARM PAIN; ARTHRALGIA; ASTHENIA; BLEEDING; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL EMBOLISM; CHRONIC URTICARIA; COGNITIVE DEFECT; COLD URTICARIA; DERMATITIS; DIABETES MELLITUS; DIZZINESS; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; FATIGUE; FRACTURE; GASTROINTESTINAL SYMPTOM; HANGOVER; HEART ARRHYTHMIA; HUMAN; HYPERSENSITIVITY; HYPERTENSION; INFECTION; LEARNING; LEG PAIN; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; METHEMOGLOBINEMIA; MONOTHERAPY; NONHUMAN; OSTEOPOROSIS; OTALGIA; PAIN; PATIENT SAFETY; PEPTIC ULCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; PSYCHOMOTOR DISORDER; QT PROLONGATION; QUALITY OF LIFE; RASH; REM SLEEP; REVIEW; SEDATION; SIDE EFFECT; SKIN NECROSIS; SOMNOLENCE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; QUALITY OF LIFE; URTICARIA;

EID: 83955162925     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04185.x     Document Type: Review

References (66)

1. 2LEN/EDFWAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1417-1426.
2. O'Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136: 197-201. (Pubitemid 27062719)
3. Baiardini I, Giardini A, Pasquali M, et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58: 621-623. (Pubitemid 36831317)
4. Grattan CE, Humphreys F,. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol 2007; 157: 1116-1123. (Pubitemid 350115711)
5. 2LEN/EDFWAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1427-1443.
6. Kaplan AP, Greaves M,. Pathogenesis of chronic urticaria. Clin Exp Allergy 2009; 39: 777-787.
7. Hide M, Francis DM, Grattan CE, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328: 1599-1604. (Pubitemid 23151920)
8. Tong LJ, Balakrishnan G, Kochan J, et al. Assessment of autoimmunity in patients with chronic urticaria. J Allergy Clin Immunol 1997; 99: 461-465. (Pubitemid 27173082)
9. Guerra L, Vicenzi C, Marchesi E, et al. Loratadine and cetirizine in the treatment of chronic urticaria. J Eur Acad Dermatol 1994; 3: 148-152. (Pubitemid 24135689)
10. Dubertret L, Murrieta Aguttes M, Tonet J,. Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. J Eur Acad Dermatol Venereol 1999; 12: 16-24. (Pubitemid 29132981)
11. Breneman DL,. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother 1996; 30: 1075-1079. (Pubitemid 26332861)
12. Ortonne JP, Grob JJ, Auquier P, Dreyfus I,. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol 2007; 8: 37-42. (Pubitemid 46998562)
13. Kaplan AP, Spector SL, Meeves S, et al. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2005; 94: 662-669. (Pubitemid 40847153)
14. Nettis E, Colanardi MC, Barra L, et al. Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2006; 154: 533-538. (Pubitemid 43382664)
15. Brostoff J, Fitzharris P, Dunmore C, et al. Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. Allergy 1996; 51: 320-325. (Pubitemid 26232824)
16. Gimenez-Arnau A, Pujol RM, Ianosi S, et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy 2007; 62: 539-546. (Pubitemid 46608361)
17. Handa S, Dogra S, Kumar B,. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatolog Treat 2004; 15: 55-57. (Pubitemid 38252098)
18. Maurer M, Ortonne JP, Zuberbier T,. Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. Br J Dermatol 2009; 160: 633-641.
19. Kozel MM, Sabroe RA,. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004; 64: 2515-2536. (Pubitemid 39587219)
20. 2LEN position paper. Allergy 2010; 65: 459-466.
21. Juniper EF, Stahl E, Doty RL, et al. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol 2005; 115 (Suppl. 1): S390-S413. (Pubitemid 40326191)
22. Runge JW, Martinez JC, Caravati EM, et al. Histamine antagonists in the treatment of acute allergic reactions. Ann Emerg Med 1992; 21: 237-242.
23. Bleehen SS, Thomas SE, Greaves MW, et al. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study. Br J Dermatol 1987; 117: 81-88. (Pubitemid 17096140)
24. 2-receptors. Br J Clin Pharmacol 1999; 48: 216-222. (Pubitemid 29349458)
25. Kosoglou T, Salfi M, Lim JM, Batra VK, Cayen MN, Affrime MB,. Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine. Br J Clin Pharmacol 2000; 50: 581-589. (Pubitemid 32010018)
26. Tagamet [prescribing information]. GlaxoSmithKline UK, Middlesex, England, 2008.
27. Simons FE, Sussman GL, Simons KJ,. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. J Allergy Clin Immunol 1995; 95: 685-693.
28. Jauregui I, Ferrer M, Montory J, et al. Antihistamines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol 2007; 17 (Suppl. 2): 41-52. (Pubitemid 351252754)
29. Nettis E, Colanardi MC, Paradiso MT, Ferrannini A,. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004; 34: 1401-1407. (Pubitemid 39233695)
30. Bagenstose SE, Levin L, Bernstein JA,. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 2004; 113: 134-140. (Pubitemid 38096173)
31. Reimers A, Pichler C, Helbling A, et al. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy 2002; 32: 1763-1768. (Pubitemid 35463863)
32. Di Gioacchino M, Di Stefano F, Cavallucci E, et al. Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation. Allergy Asthma Proc 2003; 24: 285-290. (Pubitemid 37152336)
33. Grattan CE, O'Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol 2000; 143: 365-372. (Pubitemid 30650407)
34. Vena GA, Cassano N, Colombo D, et al. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006; 55: 705-709. (Pubitemid 44444850)
35. Criado RF, Criado PR, Martins JE, Valente NY, Michalany NS, Vasconcellos C,. Urticaria unresponsive to antihistaminic treatment: an open study of therapeutic options based on histopathologic features. J Dermatolog Treat 2008; 19: 92-96. (Pubitemid 351891545)
36. Engin B, Ozdemir M,. Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2008; 22: 481-486. (Pubitemid 351436921)
37. Cassano N, D'Argento V, Filotico R, Vena GA,. Low-dose dapsone in chronic idiopathic urticaria: preliminary results of an open study. Acta Derm Venereol 2005; 85: 254-255. (Pubitemid 40695172)
38. Morgan M, Khan DA,. Therapeutic alternatives for chronic urticaria: an evidence-based review, part 1. Ann Allergy Asthma Immunol 2008; 100: 403-412. (Pubitemid 351668774)
39. Shahar E, Bergman R, Guttman-Yassky E, Pollack S,. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol 2006; 45: 1224-1227. (Pubitemid 44560379)
40. Asero R, Tedeschi A, Cugno M,. Heparin and tranexamic acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int Arch Allergy Immunol 2010; 152: 384-389.
41. Manesh PA, Pudupakkam VK, Holla AD, Dande T,. Effect of warfarin on chronic idiopathic urticaria. Indian J Dermatol Venereol Leprol 2009; 75: 187-189.
42. Asero R, Tedeschi A, Riboldi P, Cugno M,. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes weal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006; 117: 1113-1117.
43. Morgan M, Khan DA,. Therapeutic alternatives for chronic urticaria: an evidence-based review, part 2. Ann Allergy Asthma Immunol 2008; 100: 517-526. (Pubitemid 351829849)
44. Perez A, Woods A, Grattan CE,. Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol 2010; 162: 191-194.
45. Groffik A, Mitzel-Kaoukhov H, Magerl M, Maurer M, Staubach P,. Omalizumab-an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011; 66: 303-305.
46. Magerl M, Staubach P, Altrichter S, et al. Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol 2010; 126: 665-666.
47. Xolair [prescribing information]. Genetech, Inc., South San Francisco, CA, 2010.
48. Finn AF Jr, Kaplan AP, Fretwell R, et al. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999; 104: 1071-1078. (Pubitemid 29532131)
49. Nelson HS, Reynolds R, Mason J,. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000; 84: 517-522. (Pubitemid 30365414)
50. Gimenez-Arnau A, Izquierdo I, Maurer M,. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo-controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol 2009; 23: 1088-1091.
51. Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010; 125: 676-682.
52. Kameyoshi Y, Tanaka T, Mihara S, et al. Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: an open study of 21 patients. Br J Dermatol 2007; 157: 803-804. (Pubitemid 47389865)
53. Asero R,. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol 2007; 32: 34-38. (Pubitemid 46006362)
54. Siebenhaar F, Degener F, Zuberbier T, et al. High-dose desloratadine decreases weal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009; 123: 672-679.
55. Weller K, Maurer M, Gopalan G,. Desloratadine inhibits human skin mast cell activation and histamine release. J Investig Dermatol 2009; 129: 2723-2726.
56. Wang YH, Tache Y, Harris AG, et al. Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique. Allergy 2005; 60: 117-124.
57. Tanigawara Y,. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000; 22: 137-140. (Pubitemid 30083115)
58. Chen C, Hanson E, Watson JW, Lee JS,. P-glycoprotein limits the brain penetration of non-sedating but not sedating H1-antagonists. Drug Metab Dispos 2003; 31: 312-318. (Pubitemid 36249686)
59. Tashiro M, Sakurada Y, Iwabuchi K, et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 2004; 44: 890-900. (Pubitemid 38971571)
60. Barbanoj MJ, Garcia-Gea C, Antonijoan R, et al. Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Hum Psychopharmacol 2006; 21: 13-16.
61. Gupta A, Gillard M, Christophe B, et al. Peripheral and central H1 histamine receptor occupancy by levocetirizine, a non-sedating antihistamine; a time course study in the guinea pig. Br J Pharmacol 2007; 151: 1129-1136. (Pubitemid 47195533)
62. Hindmarch I, Shamsi Z, Kimber S,. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002; 32: 133-139. (Pubitemid 34226939)
63. Devillier P, Roche N, Faisy C,. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine, and levocetirizine: a comparative review. Clin Pharmacokinet 2008; 47: 217-230. (Pubitemid 351367433)
64. Tashiro M, Horikawa E, Mochizuki H, et al. Effects of fexofenadine and hydroxyzine on brake reaction time during car-driving with cellular phone use. Hum Psychopharmacol 2005; 20: 501-509. (Pubitemid 41489462)
65. Hindmarch I, Shamsi Z, Stanley N, Fairweather DB,. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999; 48: 200-206. (Pubitemid 29349456)
66. Banfield C, Padhi D, Glue P, Herron JM, Statkevich P, Affrime MB,. Electrocardiographic effects of multiple high doses of desloratadine. J Allergy Clin Immunol 2000; 104: S383. Abstract 1119.